Biotech Values

[Jonathan Robinson]

I stopped following MON as much over last year and was starting to look at it again, but it seems expensive, even after the crash with a forward PE in the mid- to high-teens for mid-teens growth. Is there some potential step-change higher in net at some point in next few years, or is this likely to be a steady grower from the much lower base?

Jon